Bristol-Myers Squibb Co
We want to boost our ownership of a portfolio stock that just boosted its dividend
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Thursday markets: Stocks are taking a breather after Wednesday’s big surge, especially in the Nasdaq Composite and the more narrow “Magnificent Seven” cohort. The yield on […]
Read More
Healthy Returns: Wall Street mulls over Amgen’s weight loss drug data
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Wall Street is chewing over critical […]
Read More
Our newest portfolio stock backed off its recent 52-week high — so we’re buying more
We’re buying 300 shares of Bristol-Myers Squibb at roughly $58 each. Following Wednesday’s trade, Jim Cramer’s Charitable Trust will own 900 shares of BMY, increasing its weighting to about 1.5% from 1%. Shares of pharmaceutical maker Bristol-Myers have dropped about 3% in the past two days in the absence of any real news. The stock […]
Read More
Stocks making the biggest moves midday: AbbVie, Tesla, Cigna, Morgan Stanley and more
Check out the companies making headlines in midday trading. Tesla — The electric vehicle stock popped 7% to build on last week’s 29% gain as investors bet that a Trump administration would fare well for the company and CEO Elon Musk. AbbVie — Shares tumbled 12% after the pharmaceutical company said its experimental schizophrenia drug […]
Read More
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street’s expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs […]
Read More
Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more
Check out the companies making headlines in midday trading: Bristol-Myers Squibb — The drug maker jumped more than 3% after the U.S. Food and Drug Administration approved a highly anticipated schizophrenia drug , the first novel type of treatment for the chronic mental disorder in more than seven decades. Bristol-Myers Squibb expects the twice-daily pill, […]
Read More
10 things to watch in the stock market Friday including a bullish call on Best Buy
10 things to watch Friday, Sept. 27 1. The S & P 500 was looking at a slightly higher open Friday after another record high close. The 10-year Treasury yield was finally lower following a tame August reading on the Fed’s favorite inflation gauge, the PCE price index. With just a couple trading days left […]
Read More
Stocks making the biggest moves premarket: Bristol-Myers Squibb, Costco, Super Micro Computer and more
Check out the companies making headlines in premarket trading: Bristol-Myers Squibb — The biopharmaceutical stock jumped 5.3% after the U.S. Food and Drug Administration approved Cobenfy as a treatment of schizophrenia for adults. It marks the first new type of treatment for the mental disorder in several decades. Novo Nordisk — U.S.-listed shares of the […]
Read More
FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades
Bristol Myers Squibb’s Cobenfy drug Courtesy: Bristol Myers Squibb The Food and Drug Administration on Thursday approved Bristol Myers Squibb‘s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, […]
Read More
Here’s where to invest $1 million, according to the pros
Volatility was the name of the game as markets entered the second half of the year, with stocks going through wild swings since July. The U.S. Federal Reserve made its first cut in four years — and more are expected to come. Some are also calling for investors to move out of cash with rates […]
Read More